CN101184493A - 用乙胺嘧啶及类似物治疗肌萎缩性侧索硬化 - Google Patents

用乙胺嘧啶及类似物治疗肌萎缩性侧索硬化 Download PDF

Info

Publication number
CN101184493A
CN101184493A CNA2006800153119A CN200680015311A CN101184493A CN 101184493 A CN101184493 A CN 101184493A CN A2006800153119 A CNA2006800153119 A CN A2006800153119A CN 200680015311 A CN200680015311 A CN 200680015311A CN 101184493 A CN101184493 A CN 101184493A
Authority
CN
China
Prior art keywords
sod
pyrimethamine
alkyl
als
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800153119A
Other languages
English (en)
Chinese (zh)
Inventor
S·斯科特
D·本杰明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALSGEN LLC
Original Assignee
ALSGEN LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALSGEN LLC filed Critical ALSGEN LLC
Publication of CN101184493A publication Critical patent/CN101184493A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polyurethanes Or Polyureas (AREA)
CNA2006800153119A 2005-03-04 2006-03-01 用乙胺嘧啶及类似物治疗肌萎缩性侧索硬化 Pending CN101184493A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65850505P 2005-03-04 2005-03-04
US60/658,505 2005-03-04

Publications (1)

Publication Number Publication Date
CN101184493A true CN101184493A (zh) 2008-05-21

Family

ID=36953835

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800153119A Pending CN101184493A (zh) 2005-03-04 2006-03-01 用乙胺嘧啶及类似物治疗肌萎缩性侧索硬化

Country Status (10)

Country Link
US (1) US20060211645A1 (https=)
EP (1) EP1917017B1 (https=)
JP (1) JP2008531710A (https=)
CN (1) CN101184493A (https=)
AT (1) ATE456953T1 (https=)
AU (1) AU2006220919A1 (https=)
CA (1) CA2600067A1 (https=)
DE (1) DE602006012115D1 (https=)
ES (1) ES2340708T3 (https=)
WO (1) WO2006096405A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104398517A (zh) * 2014-11-28 2015-03-11 四川大学 乙胺嘧啶的新用途及治疗肿瘤的药物组合物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060205704A1 (en) * 2005-03-04 2006-09-14 Alsgen, Llc Modulation of neurodegenerative diseases through the progesterone receptor
WO2006096415A2 (en) * 2005-03-04 2006-09-14 Alsgen, Llc Modulation of neurodegenerative diseases through the estrogen receptor
US20070135437A1 (en) * 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
US20080153094A1 (en) * 2006-10-13 2008-06-26 Minor James M Reduction of nonspecific binding in nucleic acid assays and nucleic acid synthesis reactions
US20110092554A1 (en) * 2007-11-19 2011-04-21 Richard Chesworth 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
WO2009086277A1 (en) 2007-12-20 2009-07-09 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
EP2432776B1 (en) * 2009-05-21 2019-09-11 Universite Laval Methyl sulfanyl pyrimidines useful as antiinflammatories, analgesics, and antiepileptics
GB201015079D0 (en) 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
MX354412B (es) 2011-06-10 2018-03-05 Merck Patent Gmbh Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton.
WO2021096199A1 (ko) * 2019-11-11 2021-05-20 에스케이케미칼 주식회사 피리메타민을 유효성분으로 포함하는 면역 관련 질환의 치료 또는 예방용 약학 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231170A (en) * 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5866562A (en) * 1996-10-25 1999-02-02 Bayer Aktiengesellschaft Ring-bridged bis-quinolines
US7442629B2 (en) * 2004-09-24 2008-10-28 President & Fellows Of Harvard College Femtosecond laser-induced formation of submicrometer spikes on a semiconductor substrate
KR101031720B1 (ko) * 2001-11-28 2011-04-29 비티지 인터내셔널 리미티드 질소함유 헤테로아릴 화합물을 함유하는 알츠하이머병의예방약 또는 치료약 또는 아밀로이드 단백질 섬유화억제제
MXPA04008901A (es) * 2002-03-13 2004-11-26 Euro Celtique Sa Pirimidinas arilo sustituidas y el uso de las mismas.
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US20060205704A1 (en) * 2005-03-04 2006-09-14 Alsgen, Llc Modulation of neurodegenerative diseases through the progesterone receptor
US20070135437A1 (en) * 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104398517A (zh) * 2014-11-28 2015-03-11 四川大学 乙胺嘧啶的新用途及治疗肿瘤的药物组合物

Also Published As

Publication number Publication date
US20060211645A1 (en) 2006-09-21
AU2006220919A1 (en) 2006-09-14
WO2006096405A8 (en) 2008-04-10
DE602006012115D1 (de) 2010-03-25
ATE456953T1 (de) 2010-02-15
EP1917017A2 (en) 2008-05-07
ES2340708T3 (es) 2010-06-08
EP1917017B1 (en) 2010-02-03
JP2008531710A (ja) 2008-08-14
WO2006096405A3 (en) 2007-05-18
WO2006096405A2 (en) 2006-09-14
CA2600067A1 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
Wang et al. Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor
US20230129598A1 (en) Methods of treating estrogen receptor-associated diseases
Ruat et al. Targeting of Smoothened for therapeutic gain
RU2712222C2 (ru) Терапевтическое средство против рака желчных протоков
Stepulak et al. Fluoxetine inhibits the extracellular signal regulated kinase pathway and suppresses growth of cancer cells
US20150359849A1 (en) Methods of increasing neuronal connectivity and/or treating a neurodegenerative condition
WO2008067389A2 (en) Modulation of sod protein synthesis for the treatment of neurodegenerative diseases
WO2007147330A1 (en) The application of the bakuchiol compounds
CN101184493A (zh) 用乙胺嘧啶及类似物治疗肌萎缩性侧索硬化
US20240342173A1 (en) Calmodulin inhibitors, chk2 inhibitors and rsk inhibitors for the treatment of ribosomal disorders and ribosomapathies
CN107624116A (zh) 具有抗癌活性的肽以及均含有该肽作为活性成分的用于预防和治疗癌症的药物组合物和膳食补充组合物
US9682982B2 (en) Inhibitors of adapter associated kinase 1, compositions comprising them, and methods of their use
AU2014363428B2 (en) A chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder
Liu et al. Menthol induces apoptosis and inhibits proliferation and migration of nonsmall cell lung carcinoma in vitro and in vivo through Akt pathway
JP2022511266A (ja) 陰性症状および障害を処置するため、神経可塑性を増大するため、ならびに神経保護を促進するためのロルペリドンの使用
Gao et al. Dopamine receptor signaling regulates fibrotic activation of retinal pigmented epithelial cells
CN101222850A (zh) 治疗对药物有抗性的癌症的方法
US20100260772A1 (en) Methods for treating or preventing diseases associated with low bone mass
Ndong et al. Cloning and pharmacological characterization of the dog cannabinoid CB2 receptor
Han et al. The combination of tetracyclines effectively ameliorates liver fibrosis via inhibition of EphB1/2
US12194027B2 (en) Small molecule inhibitors of GPCR GPR68 and related receptors for treating cancer, glioblastoma, and other indications
Idrizi et al. Striatal but not frontal cortical up-regulation of the epidermal growth factor receptor in rats exposed to immune activation in utero and cannabinoid treatment in adolescence
Sun et al. Dexmedetomidine attenuates propofol‐induced apoptosis of neonatal hippocampal astrocytes by inhibiting the Bcl2l1 signalling pathway
US20200316087A1 (en) Novel combination therapy for anxiety disorders, epilepsy, and pain
Yeh et al. Effects of a verbenachalcone derivative on neurite outgrowth, inhibition of caspase induction and gene expression

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080521